First patient recruited to the EAGLE FM Trial
9 March 2015
Evaluation of Groin Lymphadenectomy Extent for Metastatic Melanoma (EAGLE FM) clinical trial has recruited its first patient.
Professor Spillane, in collaboration with a number of other leading experts and Australia and New Zealand Melanoma Trials Group (ANZMTG) have developed a clinical trial which will further investigate a more rational evidence base for the appropriate management of metastatic melanoma in the groin lymph nodes.
The ANZMTG 01.12 EAGLE FM Trial is a multi-centre, phase III, prospective, randomised clinical trial comparing complete inguinal lymphadenectomy (groin lymph nodes dissection) and complete ilio-inguinal lymphadenectomy (groin and pelvic lymph nodes dissection) for patients with metastatic melanoma to the groin LNs and no evidence of pelvic disease on PET/CT Scan.
The trial has received broad interest from top national and international clinicians. The trial is currently open at MIA and anticipated to open at other major institutions in Australia including Peter MacCallum Cancer Centre (NSW) and Mater Hospitals (QLD).
The 2021 Australasian Melanoma Conference (AMC2021) will held in Sydney, Australia.
Drug therapy set to become standard treatment in high-risk early stage patients to stop disease spread
Prof Long AO has been recognised by Australian Academy of Health and Medical Sciences for her transformative work advancing melanoma treatments.
COVID restrictions continue to impact fundraising for melanoma services in Riverina.
Ben Garrow lost his life to melanoma. In his honour his family has established a scholarship to support a PhD student whose work focuses on saving lives from melanoma.
More than 150 clinicians, researchers and MIA staff gathered online to share research highlights.
Independent researchers at The University of Sydney are seeking patient feedback.
A re-cap of the wonderful, and often very creative, community fundraising initiatives over the April to June quarter.
Our patients who donate their tissue samples and records to our research are helping to make a difference to the lives of future melanoma patients.
MIA researchers have recently been awarded two competitive funding grants, which will help facilitate their ground-breaking work in melanoma research.
Celebrate the 10th anniversary of Amie St Clair Melanoma at the Annual Ball in Wagga Wagga!
Postponed to early 2022. Melanoma survivor Matt Kean is doing a 1000km bike ride around the Riverina to increase awareness of melanoma and raise funds for Amie St Clair Melanoma - MIA. There are many ways you can be part of this life-changing ride!
Riverina patients gain access to potentially life saving immunotherapy treatment close to home.
MIA's Prof Scolyer has been appointed as an Officer (AO) of the Order of Australia.
In a breakthrough which could extend to the treatment of other cancers, a new immune checkpoint inhibitor has proven effective in helping save the lives of advanced melanoma patients.
Whilst our research and clinical teams are trialling new treatments to save lives, it is our nurses who are on the front line providing care and support.
The easing of COVID restrictions has meant the return of community events, and we recognise the generous support of our community fundraisers.
Melanoma patients and their carers are being urged to participate in a ground-breaking survey which will shape the future of melanoma treatment, research, support and funding in Australia.